Literature DB >> 14639388

Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation.

Tracy D Kuykendall1, Bruce R Smoller.   

Abstract

Acute graft-versus-host disease is a serious and common complication after allogeneic bone-marrow transplantation, occurring in more than 20% of HLA antigen-identical sibling transplants and unrelated donor transplants. Bone-marrow transplantation is considered standard therapy for several hematologic malignancies and several nonhematologic disorders. In this retrospective study, we searched our institutional dermatopathology database between January 1998 and November 2002 for patients in whom skin biopsy specimens were examined less than 3 weeks after bone-marrow transplantation. A total of 40 slides from 38 patients were examined for the presence of the histologic features characteristic of acute graft-versus-host disease. Specimens of skin biopsies examined in the study varied from 3 to 21 days, with a mean of 12 days, status post-bone-marrow transplantation. The histologic findings of the 40 slides we examined were nonspecific and could be accounted for by a number of diagnoses. In summary, we propose that skin biopsies need not be preformed before 3 weeks status post-bone-marrow transplantation if the sole purpose is to rule out acute graft-versus-host disease.

Entities:  

Mesh:

Year:  2003        PMID: 14639388     DOI: 10.1016/s0190-9622(03)02098-x

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation.

Authors:  Skylar Klager; Mario E Lacouture; Margaret Hannum; Sean M Devlin; Molly Maloy; Melissa Pulitzer; Ann A Jakubowski; Alina Markova
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-12       Impact factor: 5.742

Review 2.  The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease.

Authors:  Jarosław Biliński; Marcin Jasiński; Grzegorz W Basak
Journal:  Biomedicines       Date:  2022-04-01

3.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

Authors:  Andrew C Harris; Rachel Young; Steven Devine; William J Hogan; Francis Ayuk; Udomsak Bunworasate; Chantiya Chanswangphuwana; Yvonne A Efebera; Ernst Holler; Mark Litzow; Rainer Ordemann; Muna Qayed; Anne S Renteria; Ran Reshef; Matthias Wölfl; Yi-Bin Chen; Steven Goldstein; Madan Jagasia; Franco Locatelli; Stephan Mielke; David Porter; Tal Schechter; Zhanna Shekhovtsova; James L M Ferrara; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-16       Impact factor: 5.742

4.  Inpatient Management of Mucocutaneous GVHD.

Authors:  Toral Vaidya; Christian Menzer; Doris M Ponce; Alina Markova
Journal:  Curr Dermatol Rep       Date:  2019-11-11

5.  Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology.

Authors:  Rachel E Reingold; Jilliana Monnier; Marco Ardigò; Joseph R Stoll; Maria C Pena; Japbani K Nanda; Stephen W Dusza; Josel D Ruiz; Lisa Flynn; Antara Afrin; Elizabeth G Klein; Susan E Prockop; Melissa P Pulitzer; Doris M Ponce; Alina Markova; Manu Jain
Journal:  Transplant Cell Ther       Date:  2021-09-24

6.  Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.

Authors:  Mª Carmen Herrero-Sánchez; Concepción Rodríguez-Serrano; Julia Almeida; Laura San Segundo; Susana Inogés; Ángel Santos-Briz; Jesús García-Briñón; Luis Antonio Corchete; Jesús F San Miguel; Consuelo Del Cañizo; Belén Blanco
Journal:  J Hematol Oncol       Date:  2016-10-20       Impact factor: 17.388

7.  Application of latent class analysis in diagnosis of graft-versus-host disease by serum markers after allogeneic haematopoietic stem cell transplantation.

Authors:  Maedeh Amini; Anoshirvan Kazemnejad; Aliakbar Rasekhi; Farid Zayeri; Abbas Hajifathali; Farzaneh Tavakoli
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

8.  A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.

Authors:  Michael Pratta; Sophie Paczesny; Gerard Socie; Natalie Barkey; Hao Liu; Sherry Owens; Michael C Arbushites; Mark A Schroeder; Michael D Howell
Journal:  Br J Haematol       Date:  2022-06-11       Impact factor: 8.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.